Birchview Capital LP Takes $558,000 Position in Immunome, Inc. $IMNM

by · The Markets Daily

Birchview Capital LP purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 60,000 shares of the company’s stock, valued at approximately $558,000. Birchview Capital LP owned about 0.07% of Immunome at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Balyasny Asset Management L.P. bought a new stake in Immunome during the 2nd quarter worth approximately $1,021,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Immunome by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock worth $2,612,000 after purchasing an additional 9,686 shares during the period. Natixis acquired a new position in shares of Immunome during the second quarter worth $2,133,000. Tema Etfs LLC bought a new stake in shares of Immunome in the second quarter worth $1,074,000. Finally, Kennedy Capital Management LLC increased its holdings in Immunome by 642.6% in the second quarter. Kennedy Capital Management LLC now owns 109,352 shares of the company’s stock valued at $1,017,000 after purchasing an additional 94,627 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Trading Up 0.4%

Shares of Immunome stock opened at $19.57 on Friday. The business’s fifty day simple moving average is $16.94 and its 200 day simple moving average is $12.24. The firm has a market capitalization of $1.79 billion, a P/E ratio of -6.63 and a beta of 2.17. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $20.80.

Immunome (NASDAQ:IMNM – Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. Analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IMNM shares. Guggenheim reissued a “buy” rating and issued a $25.00 price target on shares of Immunome in a research note on Monday, August 25th. Truist Financial began coverage on Immunome in a research report on Monday, December 1st. They set a “buy” rating and a $36.00 target price on the stock. Craig Hallum began coverage on shares of Immunome in a report on Friday, September 5th. They issued a “buy” rating and a $26.00 price target for the company. Wedbush reissued an “outperform” rating and set a $21.00 price objective on shares of Immunome in a research report on Friday, November 7th. Finally, The Goldman Sachs Group began coverage on Immunome in a research note on Monday, September 22nd. They issued a “buy” rating and a $26.00 price objective for the company. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $25.00.

Read Our Latest Stock Analysis on Immunome

Immunome Company Profile

(Free Report)

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Featured Stories